Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type 1 and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study)

References

• Gilbert C, Foster A. Childhood blindness in the context of VISION 2020--the right to sight. Bull World Health Organ. 2001;79(3):227–232.
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603–615. doi:10.1056/NEJMoa1007374
   PubMed Web of Science ®Google Scholar
• Good WV; Good WV; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–250.
   PubMedGoogle Scholar
• Hartnett ME. Retinopathy of prematurity: evolving treatment with anti-vascular endothelial growth factor [published correction appears in Am J Ophthalmol. 2021 Nov; 231:213]. Am J Ophthalmol. 2020;218:208–213. doi:10.1016/j.ajo.2020.05.025
   PubMed Web of Science ®Google Scholar
• Jain P, Sheth J, Anantharaman G, Gopalakrishnan M. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian J Ophthalmol. 2017;65(7):596–602. doi:10.4103/ijo.IJO_992_16
   Web of Science ®Google Scholar
• Stahl A, Lepore D, Fielder A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019;394(10208):1551–1559. doi:10.1016/S0140-6736(19)31344-3
   PubMed Web of Science ®Google Scholar
• Stahl A, Sukgen EA, Wu WC, et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial. JAMA. 2022;328(4):348–359. doi:10.1001/jama.2022.10564
   PubMed Web of Science ®Google Scholar
• Narayanan R, Hariprasad SM, Sheth J. Biosimilars for the treatment of retinal diseases. Ophthalmic Surg Lasers Imaging Retina. 2021;52(5):242–246. doi:10.3928/23258160-20210429-01
   Web of Science ®Google Scholar
• Sheth JU, Stewart MW, Khatri M, et al. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: insights from the vitreoretinal society of India biosimilars of anti-VEGF Survey. Indian J Ophthalmol. 2021;69(2):352–356. doi:10.4103/ijo.IJO_2703_20
   PubMed Web of Science ®Google Scholar
• Soman M, Nair I, Sheth JU, Nair U. Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: real-World Evidence. Ophthalmol Ther. 2022;11(3):1175–1186. doi:10.1007/s40123-022-00507-w
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Stewart MW, Sheth JU, et al. Real-world safety outcomes of intravitreal ranibizumab biosimilar (Razumab) therapy for chorioretinal diseases. Ophthalmol Ther. 2021;10(2):337–348. doi:10.1007/s40123-021-00345-2
   PubMed Web of Science ®Google Scholar
• Intas Launches Bevatas (bevacizumab) in India. Available from: https://www.bigmoleculewatch.com/2017/10/17/intas-launches-bevatas-bevacizumab-india/. Accessed September 28, 2023.
   Google Scholar
• International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991–999. doi:10.1001/archopht.123.7.991
   PubMed Web of Science ®Google Scholar
• Wallace DK, Dean TW, Hartnett ME, et al. A dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments. Ophthalmology. 2018;125(12):1961–1966. doi:10.1016/j.ophtha.2018.05.001
   PubMed Web of Science ®Google Scholar
• Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121(12):1684–1694. doi:10.1001/archopht.121.12.1684
   PubMedGoogle Scholar
• Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132(11):1327–1333. doi:10.1001/jamaophthalmol.2014.2772
   PubMed Web of Science ®Google Scholar
• Gunzenhauser RC, Lee YH, Tsui I. Rhegmatogenous retinal detachment after retinopathy of prematurity laser treatment. Am J Ophthalmol Case Rep. 2022;29:101785. doi:10.1016/j.ajoc.2022.101785
   Google Scholar
• VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB, Lambert SR. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124(5):619–633. doi:10.1016/j.ophtha.2016.12.025
   PubMed Web of Science ®Google Scholar
• Darwish D, Chee RI, Patel SN, et al. Anti-vascular endothelial growth factor and the evolving management paradigm for retinopathy of prematurity. Asia Pac J Ophthalmol. 2018;7(3):136–144.
   Web of Science ®Google Scholar
• Wang SD, Zhang GM; Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis. Int J Ophthalmol. 2020;13(5):806–815. doi:10.18240/ijo.2020.05.17
   PubMed Web of Science ®Google Scholar
• Chang E, Josan AS, Purohit R, Patel CK, Xue K. A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity. Ophthalmology. 2022;129(12):1389–1401. doi:10.1016/j.ophtha.2022.06.042
   PubMed Web of Science ®Google Scholar
• Barnett JM, Hubbard GB. Complications of retinopathy of prematurity treatment. Curr Opin Ophthalmol. 2021;32(5):475–481. doi:10.1097/ICU.0000000000000783
   PubMed Web of Science ®Google Scholar
• Murakami T, Sugiura Y, Okamoto F, et al. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2021;259(9):2849–2855. doi:10.1007/s00417-021-05137-9
   Web of Science ®Google Scholar